Səhifə 1 dan 35 nəticələr
PRIMARY OBJECTIVES:
I. To determine the safety, toxicity profile, dose limiting toxicity (DLT), maximum tolerated dose (MTD) and recommended phase 2 dose (RP2D) of copanlisib hydrochloride (copanlisib) in combination with eribulin mesylate (eribulin) in metastatic triple negative breast cancer
We hypothesize that ribociclib plus belinostat will be a well-tolerated and demonstrate activity in women with metastatic triple-negative breast or recurrent ovarian cancers.
This trial combines two targeted agents, a CDK inhibitor and a lysine deacetylase (DAC) inhibitor for use as the first
Background:
- Current greater than or equal to 2nd line treatments for metastatic breast cancer provide modest response rates, and modest improvement in progression-free survival but no treatments are curative.
- Bavarian-Nordic (BN)-Brachyury vaccine is a recombinant poxvirus vaccine against the
PRIMARY OBJECTIVE:
I. To define the role of epigenetic immune priming in a biomarker enriched estrogen receptor (ER)+ breast cancer population on the basis of overall response rate.
SECONDARY OBJECTIVES:
I. To assess duration of response (DOR) 24-week landmark progression-free survival (PFS:24).
II.
This is a Phase I/Ib study testing the safety and preliminary efficacy of olaparib and vorinostat when used together in participants with relapsed/refractory and or metastatic breast cancer. Cancer cells grow in an uncontrolled manner and this causes damage to their DNA (genetic makeup). Cancer
This research study is a Pilot Study, which is the first time investigators are examining this study imaging agent in patients who have breast cancer.
The FDA (the U.S. Food and Drug Administration) has approved [11C]Martinostat as an investigational tracer (a type of dye used to for radiographic
PRIMARY OBJECTIVES:
I. To determine a safe dose of niraparib when combined with radium Ra 223 dichloride (radium-223) in patients with metastatic castrate-resistant prostate cancer (mCRPC) that have and have not received prior chemotherapy.
SECONDARY OBJECTIVES:
I. To determine the proportion of
Colorectal cancer (CRC) is one of the most common forms of cancer and the second leading cause of cancer-related deaths in the western world, accounting for the annual death of 215.000 europeans in 2012 and an estimated 50.310 Americans in 2014.
Sporadic CRC develops through the accumulation of
1. Introduction to investigational treatment(s) and other study treatment(s)
1.1 Overview of gemcitabine Gemcitabine (29,29-difluoro 29-deoxycytidine, dFdC) which developed from cytosine arabinoside (Ara-C) is an nucleoside analog used as chemotherapy. It was intended as an antiviral drug in
This is a phase I multi-center dose escalation study of the histone deacetylase inhibitor (HDACi) HBI-8000 when given in combination with paclitaxel and trastuzumab in women with advanced or metastatic HER2+ breast cancer.
Three dose levels of HBI-8000 (15 mg, 20 mg, and 25 mg) will be tested using
Controlled human exposure studies to ozone have reported decreases in lung function (Devlin et al. 2012; Kim et al. 2011) and increased inflammation (Kim et al. 2011; Koren et al. 1991; Liu et al. 2009; Romieu et al. 2008). However, the range of response to ozone in healthy young volunteers is an
Unique aspects of this study:
This is the first study to look at the response of hormone therapy resistance breast cancer to epigenetic immune priming. It is also the first study to look at the combination of an Histone deacetylase (HDAC) inhibitor (vorinostat), an anti-estrogen (tamoxifen) and a
PRIMARY OBJECTIVES:
I. To evaluate the feasibility of using talazoparib prior to initiating standard neoadjuvant therapies.
II. To evaluate the toxicity profile in women taking talazoparib in the neoadjuvant setting.
SECONDARY OBJECTIVES:
I. To provide first estimate of clinical response to
OBJECTIVES
Primary
To determine the change from baseline to post-treatment Ki67 values in ER-positive, HER2-negative ILC tissue derived from postmenopausal women awaiting definitive surgery or further neoadjuvant treatment who are randomized to 21-24 days of neoadjuvant endocrine treatments with
Breast cancer is the most common cancer amongst women worldwide, with a lifetime risk of 7-8% in women and incidence rates ranging from 19.3-89.7 per 100,000 women in developing and developed countries. More than 1,383,500 cases of invasive breast cancer are estimated to be diagnosed worldwide,and